miRNAs have been also characterized recently as potential oncogenes that promote the development of human B-cell lymphoma (miR-17-92 cluster) [57] and the proliferation and tumorigenesis of primary human cells (miR-372 and miR-373) by neutralizing p53-mediated CDK inhibition [58]. The gene discussed is TP53; the disease is B-cell non-Hodgkin lymphoma.